InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,346.56
(
-1.84%
)
US TECH 100
17,900.00
(
-2.65%
)
Dow Jones
39,737.26
(
-1.51%
)
Brent Oil
77.36
(
0.00%
)
Bitcoin
60,510.80
(
-0.26%
)
Post# of 252783
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

vinmantoo

Send PM Follow Ignore
Followers 30
Posts 4181
Boards Moderated 0
Alias Born 07/25/2007

vinmantoo

Re: NP1986 post# 135278

Wednesday, 01/18/2012 1:07:48 PM

Wednesday, January 18, 2012 1:07:48 PM

Post# of 252783
Overall survival is the metric that won approval for Nexavar in HCC, not PFS. Regorafenib appears to be following that pattern, so I think the focus on the small but not statistically significant increase in PFS for Regorafenib is misplaced.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up